Biomarin Pharmaceutical Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
62.7%projected annual EPS growth
Analyst Coverage
25analysts covering
FY Revenue (est.)
$3.9Bnext fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 26 Oct 2026 |
Monitoring Framework
Key Performance Indicators
Total Revenues Quarterly766MTarget: 3,825,000,000 to 3,925,000,000
Enzyme Therapies Revenue Quarterly514MTarget: 2,725,000,000 to 2,775,000,000
VOXZOGO Revenue Quarterly220MTarget: Unchanged from prior guidance
Watch Items
- Amicus Therapeutics IntegrationTrigger: Synergy realization and post-close operating expense dilutionAction: Monitor integration progress, operating margins, and commercial performance of Galafold and Pombiliti + Opfolda.
- VOXZOGO Label Expansion in HypochondroplasiaTrigger: Phase 3 pivotal study results and regulatory filingsAction: Track regulatory submission timelines and commercial launch preparation following positive Phase 3 data.
- BMN 401 Clinical ProgressTrigger: Phase 3 trial updates in children with ENPP1 DeficiencyAction: Evaluate clinical data readouts and safety profiles to assess long-term pipeline viability.
Research as of 2 Sep 2026